FDA Guidance for Clinical Investigators, Sponsors and IRBs Regarding Adverse Event Reporting in GCP Regulated Environments

November 15, 2019
Previous
The Future of the FDA: Operating in an 'Electronic World'
The Future of the FDA: Operating in an 'Electronic World'

Over the past few years, the FDA and the industries it regulates have recognized the need for a modern infr...

Next Flipbook
Solutions to 21 CFR Part 111 Challenges
Solutions to 21 CFR Part 111 Challenges

The rapidly-growing nutraceutical industry is moving into an era of increased government oversight and tigh...